CryoPort (CYRX) vs Nektar Therapeutics (NKTR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CryoPort (CYRX) has outperformed Nektar Therapeutics (NKTR) over the past year, gaining 117.0% versus a loss of 44.4%. Over five years, CYRX leads with a -71.4% price change compared with -82.0% for NKTR. Nektar Therapeutics is the larger company by market cap ($1.03 billion vs $964.9 million), about 1.1 times the size, while CryoPort is growing revenue faster (+12.4% vs -43.9%).
CryoPort converts more of its revenue into profit, with a net margin of 44.4% versus -297.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYRX | NKTR |
|---|---|---|
| Share price | $19.05 | $30.20 |
| Market cap | $964.87M | $1.03B |
| 1-day change | -2.56% | -7.19% |
| YTD return | +98.44% | -28.57% |
| 1-year return | +116.97% | -44.36% |
| 5-year return | -71.38% | -82.04% |
| EPS (TTM) | $-0.90 | $-22.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $176.18M | $55.23M |
| Revenue growth (YoY) | +12.38% | -43.89% |
| Net income (latest FY) | $78.30M | $-164.08M |
| Gross margin | 47.14% | 100.00% |
| Operating margin | -20.89% | -253.66% |
| Net margin | 44.44% | -297.07% |
| 52-week high | $21.78 | $109.00 |
| 52-week low | $7.61 | $30.13 |
| Distance from 52-week high | -12.53% | -72.29% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +17.22% | +336.82% |
| Average volume | 843.80K | 1.12M |
| Shares outstanding | 50.65M | 34.21M |
| Employees | 684 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CYRX has outperformed NKTR by 161.3 percentage points over the past year.
- CryoPort is more profitable, keeping 44.4 cents of every revenue dollar as net income versus -297.1 cents for Nektar Therapeutics.
- CryoPort grew revenue faster in its latest fiscal year (+12.38% vs -43.89%).
About CryoPort
CYRX stock →Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 684 employees
About Nektar Therapeutics
NKTR stock →Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
CYRX vs NKTR FAQ
Which is bigger, CryoPort or Nektar Therapeutics?
Nektar Therapeutics (NKTR) is larger, with a market capitalization of $1.03B compared with $964.87M for CryoPort (CYRX).
Which stock has performed better over the past year, CYRX or NKTR?
CYRX returned +116.97% over the past 12 months, compared with -44.36% for NKTR (price return, excluding dividends). Past performance does not predict future results.
Are CryoPort and Nektar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.